Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nemtabrutinib and Venetoclax as Frontline Treatment for CLL/SLL
NCT07557056Phase 2Recruiting
- Start
- Nov 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nemtabrutinib in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Primary endpoint: Minimal Residual Disease. Started Nov 2026; status: recruiting.
02
Drugs
nemtabrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT07557056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07557056.